SLC27A5抗体—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Western blot analysis using SLC27A5 mouse mAb against 3T3L1 (1) and NIH3T3 (2) cell lysate.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human liver cancer tissues using SLC27A5 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human stomach tissues using SLC27A5 mouse mAb with DAB staining.    

  
  

The SLC27A5 antibody targets the solute carrier family 27 member 5 (SLC27A5), also known as fatty acid transport protein 5 (FATP5). This transmembrane protein is primarily expressed in the liver and plays a critical role in fatty acid metabolism. SLC27A5 facilitates the uptake of long-chain fatty acids into cells and activates them via acyl-CoA synthetase activity, linking fatty acids to Coenzyme A for subsequent metabolic processes. It is particularly vital in regulating bile acid synthesis by interacting with the bile acid-CoA synthase (BACS), influencing lipid homeostasis and energy balance.

Antibodies against SLC27A5 are essential tools for studying its expression, localization, and function in metabolic pathways. Researchers use these antibodies in techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate SLC27A5's role in liver physiology and diseases such as non-alcoholic fatty liver disease (NAFLD), cholestasis, and metabolic syndrome. Studies have shown that SLC27A5 deficiency or dysfunction may alter bile acid composition, impair lipid metabolism, and contribute to metabolic disorders. Its interaction with nuclear receptors like PPARα and FXR also links it to broader regulatory networks in lipid and glucose homeostasis. By enabling precise detection of SLC27A5. these antibodies support advancements in understanding metabolic dysregulation and potential therapeutic targets.